Pacientes con deterioro cognitivo leve y reducción de la proteína Aβ1-42 en LCR evolucionan rápidamente a enfermedad de Alzheimer

Borroni, 2007, Combined biomarkers for early Azheimer disease diagnosis, Curr Med Chem, 14, 1171, 10.2174/092986707780598005 Hansson, 2006, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, 5, 228, 10.1016/S1474-4422(06)70355-6 Artero, 2006, Revised criteria for mild cognitive impairment: validation within a longitudinal population study, Dement Geriatr Cogn Disord, 22, 465, 10.1159/000096287 Zetteberg, 2003, CSF markers for prediction of Alzheimer's disease, Neuroscience Letters, 352, 67, 10.1016/j.neulet.2003.08.011 Hampel, 2004, Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment, Mol Psychiatry, 9, 705, 10.1038/sj.mp.4001473 Herukka, 2005, CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment, Neurology, 64, 1294, 10.1212/01.WNL.0000156914.16988.56 Ewers, 2007, Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI, Neurology, 69, 2205, 10.1212/01.wnl.0000286944.22262.ff Diniz, 2008, Do CSF total tau, phosphorylated tau and beta amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature, World J Biol Psychiatry, 9, 172, 10.1080/15622970701535502 Mitchell, 2009, CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies, J Neurol Neurosurg Psychiatry, 80, 966, 10.1136/jnnp.2008.167791 Monge-Argilés, 2010, Biomarcadores en LCR de pacientes con deterioro cognitivo leve: metaanálisis de su capacidad predictiva para el diagnóstico de la enfermedad de Alzheimer, Rev Neurol, 50, 193 Landau, 2010, Comparing predictors of conversion and decline in mild cognitive impairment, Neurology, 75, 230, 10.1212/WNL.0b013e3181e8e8b8 Blom, 2009, Rapid progression from mild impairment to Alzheimer's disease in subjects with elevated levels of tau in CSF and APOE ɛ4/ɛ4 genotype, Dement Geriatr Cogn Disord, 27, 458, 10.1159/000216841 Kester, 2009, CSF biomarkers predict rate of cognitive decline in Alzheimer disease, Neurology, 73, 1353, 10.1212/WNL.0b013e3181bd8271 McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 Olsson, 2005, Simultaneous measurement of β-amyloid1-42, total tau and phosphorylated tau in CSF by xMAP technology, Clin Chem, 51, 336, 10.1373/clinchem.2004.039347 Shaw, 2009, Cerebrospinal fluid biomarkers signature in Alzheimer's disease neuroimaging initiative subjects, Ann Neurol, 65, 403, 10.1002/ana.21610 Koopman, 2009, Improved discrimination of autopsy-confirmed Alzheimer's disease from non-AD dementias using CSF p-tau 181p, Neurochem Int, 55, 214, 10.1016/j.neuint.2009.02.017 Dubois, 2010, Revising the definition of Alzheimer's disease: a new lexicon, Lancet Neurol, 9, 1118, 10.1016/S1474-4422(10)70223-4 Hort, 2010, Use of CSF biomarkers in diagnosis of dementia across Europe, Eur J Neurol, 17, 90, 10.1111/j.1468-1331.2009.02753.x Vemuri, 2010, Serial MRI and CSF biomarkers in normal aging, MCI and AD, Neurology, 75, 143, 10.1212/WNL.0b013e3181e7ca82 Lewczuck, 2008, Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study, Neurobiol Aging, 29, 812, 10.1016/j.neurobiolaging.2006.12.010 Bouwman, 2007, Longitudinal changes of CSF biomarkers in memory clinic patients, Neurology, 69, 1006, 10.1212/01.wnl.0000271375.37131.04 Andreasen, 2001, Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice, Arch Neurol, 58, 373, 10.1001/archneur.58.3.373